Fibrocell Science, Inc. (FCSC)
-NYSE MKT 5.00 0.00(0.00%) May 17, 4:00PM EDT
| Prev Close: | N/A |
|---|
| Open: | 4.80 |
|---|
| Bid: | 4.85 x 200 |
|---|
| Ask: | 5.00 x 200 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | 3.85 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 4.75 - 5.75 |
|---|
| 52wk Range: | 3.00 - 7.50 |
|---|
| Volume: | 94,511 |
|---|
| Avg Vol (3m): | 19,940 |
|---|
| Market Cap: | N/A |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.72 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Fibrocell Science Announces Approval of Common Stock Listing on NYSE MKTBusiness Wire(Wed, May 15)
- FIBROCELL SCIENCE, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, May 14)
- FIBROCELL SCIENCE, INC. FinancialsEDGAR Online Financials(Thu, May 2)
- FIBROCELL SCIENCE, INC. FinancialsEDGAR Online Financials(Thu, May 2)
- Fibrocell Science Expands Potential Medical Applications for Azficel-TBusiness Wire(Thu, May 2)
- Fibrocell Science Announces One-for-Twenty-Five Reverse Stock Split - Fibrocell Has Been Cleared to Submit Listing Application to the NYSE MKTBusiness Wire(Mon, Apr 29)
- FIBROCELL SCIENCE, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, FinanciaEDGAR Online(Mon, Apr 29)
- Fibrocell Science LAVIV® Recognized as 2013 Edison Awards’ Silver WinnerBusiness Wire(Fri, Apr 26)
- Fibrocell Science Pursues Premium Aesthetic Market Position for LAVIV®Business Wire(Wed, Apr 24)
- Fibrocell Science Autologous Fibroblast Injections Show Improvement in Facial Acne Scar AppearanceBusiness Wire(Mon, Apr 15)
- Fibrocell Science Reports 2012 ResultsBusiness Wire(Tue, Apr 2)
- FIBROCELL SCIENCE, INC. Files SEC form 10-K, Annual ReportEDGAR Online(Mon, Apr 1)
- Fibrocell/UCLA Study on Human Skin Cells Yields Promising ResultsBusiness Wire(Wed, Mar 20)
- FIBROCELL SCIENCE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other EventsEDGAR Online(Thu, Mar 14)
- FIBROCELL SCIENCE, INC. Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Tue, Mar 5)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Fibrocell Science, Inc., an autologous cellular therapeutic company, together with its subsidiaries, focuses on development of various products for aesthetic, medical, and scientific applications.
View More 
0.80%